Navigation Links
Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Date:5/16/2012

SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. One of these agents, R343, an inhaled SYK inhibitor, will be entering a Phase 2 clinical study later this summer in mild to moderate asthmatic patients. The other, R256, an inhaled IL13 signaling/JAK inhibitor, is potentially useful in controlling moderate to severe as well as chronic forms of the disorder. Clinical results with R343 and research results with R256 will be presented at the upcoming American Thoracic Society Conference in San Francisco, CA this month (see details below).

"Extensive study of inflammatory conditions in the lung has led us to discover small molecule therapeutics that may be capable of disrupting the inflammatory cascade, restoring lung tissue functionality and, in cases of severe disease, preventing airway remodeling resulting in additional tissue damage," said Donald G. Payan, M.D., Rigel's co-founder and president of Discovery and Research.  "Direct delivery of R343 and R256 into the airway puts the drugs where they are needed, and may offer new options in asthma therapy that address not only the symptoms, but also the underlying causes of the disease."

Asthma
Asthma is recognized as a chronic inflammatory disorder of the lungs and respiratory passages, which often occurs in response to the presence of an allergen or pathogen. Uncontrolled or chronic inflammation associated with asthma may result in long-term damage to the airways and lungs.  In severe cases or episodes, this disorder can cause breathlessness, tissue scarring and/or death from asphyxiation.

According to the Asthma and Allergy Foundation of America, an estimated 20 million people in the U.S. have asthma. The m
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 19, 2014 ... Markets ( http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the ... Market 2014-2018" report to their offering. ... Cytogenetics involves the study of chromosomes using ... functions of genes and chromosomes. It plays ...
(Date:9/18/2014)... 18, 2014  PRO-DEX, INC. (NasdaqCM: PDEX) today announced ... full-year ended June 30, 2014. Quarter ... ended June 30, 2014 increased $492,000, or 18%, to ... ended June 30, 2013, due primarily to an increase ... from the Company,s largest customer, partially offset by an ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "China PTCA Balloon Market Investment Report, 2014-2016" ... balloon, as a indispensable medical device in percutaneous coronary ... for stent, but also as a device for pre-/post-stent ... closely related to that of PCI. As ...
Breaking Medicine Technology:Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13China PTCA Balloon Market Investment Report, 2014-2016 2China PTCA Balloon Market Investment Report, 2014-2016 3
... part of the eighth annual DVT (deep-vein thrombosis) Awareness Month, ... of DVT and its risk factors among patients with co-morbid ... respiratory and obesity patients.   DVT remains the ... deaths may be due to PE (pulmonary embolism).(1)  This is ...
... Ill., March 9, 2011 Hospira, Inc. (NYSE: ... announced U.S. Food and Drug Administration (FDA) approval of docetaxel. ... Hospira expects to launch the product later this month. ... variety of cancers. In 2010, U.S. sales of Taxotere were ...
Cached Medicine Technology:Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 2Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 3Critical Need Exists to Address Health Conditions That Put Patients at Highest Risk for Deep-Vein Thrombosis and Pulmonary Embolism 4Hospira Announces U.S. Approval of Generic Docetaxel 2
(Date:9/19/2014)... also known as Johne,s disease, is caused by ... (MAP). In Austria, there is a legal obligation ... and causes treatment-resistant diarrhoea and wasting among affected ... for commercial farms. The animals produce less milk, ... other conditions such as udder inflammation. , ...
(Date:9/19/2014)... 19, 2014 The Canton Group, Baltimore’s leading ... website for the Xaverian Brothers. The new site aligns ... encourage and edify one another through a life of Gospel ... summons “to manifest God’s care and compassionate love to the ... was developed using a responsive web design, which allows users ...
(Date:9/19/2014)... Outsourcing services provider Profit By RPO has bagged a huge ... HR outsourcing services in India. , " Profit By RPO ... act as a talent acquisition and transformation partner. Under the ... 3 locations in India in the next four months," the ... win for us and we are delighted to collaborate with ...
(Date:9/19/2014)... The dentist at Encino Esthetic Dental ... Throughout the month of September, new patients will be able ... just $69. A complimentary home teeth whitening kit will be ... gums checked and meet the team at Encino Esthetic Dental ... protect oral health. According to the American Dental Association, biannual ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- Women of ... to maintain better oral care and visit the dentist ... Centers for Disease Control and Prevention. Researchers found ... Mexican-American, as well as those with lower income and ... Oral disease, with symptoms such as cavities or ...
Breaking Medicine News(10 mins):Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:Xaverian Brothers Partner with The Canton Group to Launch New Website 2Health News:Profit By RPO Bags huge RPO contract from US-based Implementation Partner 2Health News:Encino Esthetic Dental Group is Now Offering a Special Promotion for New Patients 2Health News:Oral Health in Women of Childbearing Age Needs Improvement 2
... effects in patients with high-grade glioma from chemoradiation may ... radiation oncologists at the Kimmel Cancer Center at ... the April issue of the British Journal ... occurrence of early side effects, such as fatigue and ...
... prohibition against testosterone therapy in men with untreated or ... study published in The Journal of Urology . ... a history of prostate cancer, even if treated and ... to the belief that testosterone activated prostate cancer growth, ...
... secure emotional relationship with their parents, and particularly their mothers, ... , according to new research. The study suggests that ... have at least 30 percent higher odds for obesity by ... researchers accounted for other family-related factors that could provide alternative ...
... Dieters are so involved with trying to eat virtuously that they ... labeled as healthy, according to a new study in the ... names can work to their disadvantage. "Keeping your weight-loss goal ... you are careful to avoid pasta selections and instead order from ...
... INDIANAPOLIS Jason S. Meyer, Ph.D., assistant professor of ... University Indianapolis, will be honored by the largest eye ... which one day may lead to reversal of blindness ... of the retina. The Association for Research ...
... smoke a cigarette may not be enough to protect the ... to a new study in the American Journal of ... Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... recognized category of tobacco smokeknown as "thirdhand smoke"can have as ...
Cached Medicine News:Health News:Minimizing side effects from chemoradiation could help brain cancer patients live longer 2Health News:Study suggests another look at testosterone-prostate cancer link 2Health News:Study suggests another look at testosterone-prostate cancer link 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 2Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 3Health News:Quality of parent-toddler relationship could affect risk for childhood obesity 4Health News:When a salad is not a salad: Why are dieters easily misled by food names? 2Health News:IUPUI faculty member to receive national innovative vision research award 2Health News:LA BioMed study finds 'thirdhand smoke' poses danger to unborn babies' lungs 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: